NASDAQ: ACSTAcasti Pharma Inc Stock
$0.55+0.02 (+3.77%)
Updated May 26, 2023
ACST Price
$0.55
Fair Value Price
$1.12
Market Cap
$24.31M
52 Week Low
$0.34
52 Week High
$1.05
P/E
-1.6x
P/B
0.25x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$16M
Beta
0.96
Next Earnings
Jun 19, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ACST Overview
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACST ($0.55) is undervalued by 51.29% relative to our estimate of its Fair Value price of $1.12 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACST ($0.55) is significantly undervalued by 51.29% relative to our estimate of its Fair Value price of $1.12 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACST due diligence checks available for Premium users.
Be the first to know about important ACST news, forecast changes, insider trades & much more!
ACST News
Valuation
ACST fair value
Fair Value of ACST stock based on Discounted Cash Flow (DCF)
Price
$0.55
Fair Value
$1.12
Undervalued by
50.85%
ACST ($0.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACST ($0.55) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.6x
Industry
11.86x
Market
54.23x
ACST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.25x
Industry
5.18x
ACST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACST's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.9M
Profit Margin
0%
ACST's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$116.8M
Liabilities
$20.1M
Debt to equity
0.21
ACST's short-term assets ($33.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACST's short-term assets ($33.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
-$5.0M
Financing
$0.0
ACST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACST vs Biotech Stocks
Acasti Pharma Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.